TORONTO, Ontario, Canada, April 7, 2026
Apotex Inc., a leading global pharmaceutical company, announced that Health Canada has approved DENOZA™ (denosumab injection), a biosimilar to Prolia®, for the treatment of osteoporosis in postmenopausal women and men at high risk of fracture. The approval represents a significant advancement in expanding access to biologic therapies and improving treatment options for millions of patients affected by osteoporosis in Canada.
Regulatory Approval Expands Access to Biosimilar Therapies
The approval of DENOZA™ marks an important milestone in biosimilar drug development and regulatory progress, reinforcing the role of Health Canada in enabling access to cost-effective biologic treatments. The biosimilar has been authorized for all approved indications of the reference biologic denosumab, including treatment of osteoporosis and fracture risk reduction, and will be available in a prefilled syringe format for convenient administration.
Biosimilars are designed to be highly similar in safety, efficacy, and quality to their reference biologics, offering a more affordable alternative while maintaining strict regulatory standards. The introduction of DENOZA is expected to increase competition in the biologics market, ultimately contributing to a more sustainable healthcare system and improved patient access.
With over 2.3 million Canadians affected by osteoporosis, the availability of additional treatment options is critical to addressing this growing public health burden, particularly as the aging population continues to rise.
Advertisement
Addressing Unmet Needs in Osteoporosis Management
Osteoporosis is a chronic, progressive condition characterized by reduced bone density and increased fracture risk, often leading to significant morbidity, reduced quality of life, and increased healthcare costs. Despite the availability of treatments, the condition remains underdiagnosed and undertreated, highlighting the need for broader access to effective therapies.
Denosumab, the active component of DENOZA, works by inhibiting RANK ligand (RANKL), a key regulator of bone resorption, thereby helping to increase bone mass and reduce fracture risk. The introduction of a biosimilar version provides healthcare providers with additional flexibility in treatment selection, enabling more patients to benefit from targeted biologic therapy.
Clinical experts have emphasized that timely access to osteoporosis treatments is essential for improving patient outcomes, particularly in high-risk populations. Expanding access through biosimilars like DENOZA supports preventive care strategies and long-term disease management, reducing the burden on healthcare systems.
Strengthening Healthcare Sustainability and Patient Choice
Apotex highlighted that the approval aligns with its mission to improve access to affordable, high-quality medicines, reinforcing its role as a key player in the global biosimilar and generic pharmaceutical market. The launch of DENOZA is expected to enhance treatment accessibility while supporting healthcare cost optimization, a critical factor in modern healthcare systems.
The availability of biosimilars also encourages market competition and innovation, driving improvements in drug pricing, accessibility, and patient care standards. For healthcare providers, the addition of DENOZA expands the range of therapeutic options available, enabling more personalized and effective treatment strategies.
Furthermore, the approval reflects the continued evolution of biopharmaceutical innovation and regulatory science, where biosimilars play an increasingly important role in bridging gaps in access to advanced biologic therapies.
The approval of DENOZA™ by Health Canada represents a significant advancement in osteoporosis treatment and biosimilar adoption, providing patients and healthcare providers with a new, cost-effective therapeutic option. By expanding access to proven biologic treatments, Apotex is contributing to improved patient outcomes, healthcare sustainability, and broader adoption of innovative therapies.
As the demand for affordable biologics continues to grow, biosimilars like DENOZA will play a pivotal role in shaping the future of biopharmaceutical development, regulatory compliance, and patient-centered care.
Source: Apotex press release
